SCHEMBL1940129

SCHEMBL1940129

CC(C)(CO)NS(=O)(=O)c1cc(C(N)=O)c(Cl)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DUT P33316 1/20 0.36
CFTR P13569 3/20 0.35
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA13 Q8N1Q1 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
PTGES2 Q9H7Z7 1/20 0.32
BRAF P15056 2/20 0.32
PDE4A P27815 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1940985 0.90 CFTR (0.35) KDM4EALDH1A1DUTCFTRCA12
SCHEMBL1939267 0.85 KDM4E (0.38) KDM4EALDH1A1L3MBTL1CFTRALOX5AP
SCHEMBL1939276 0.83 KDM4E (0.40) KDM4EALDH1A1L3MBTL1DUTPTGES2
SCHEMBL1938337 0.77 GSTO1 (0.39) ALDH1A1CA12CA1CA2CA3
SCHEMBL1940126 0.76 PSEN1 (0.35) CA12CA1CA2CA3CA4
SCHEMBL1939366 0.75 KDM4E (0.39) KDM4EALDH1A1L3MBTL1DUTCA12
SCHEMBL1940976 0.74 IKBKB (0.40) KDM4EALDH1A1CA12CA1CA2
SCHEMBL5035258 0.74 ALDH1A1 (0.51) KDM4EALDH1A1L3MBTL1CA12CA1
SCHEMBL1941169 0.73 ALOX5AP (0.39) KDM4EALDH1A1L3MBTL1ALOX5APFEN1
SCHEMBL1939691 0.73 ALDH1A1 (0.49) ALDH1A1CA12CA2CA9BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1851225-B1 PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-06-15 EP claimed
JP-2008530042-A 2008-08-07 JP claimed
US-7361659-B2 Pyrrazolo-pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-04-22 US claimed
EP-1851225-A1 PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2007-11-07 EP claimed
US-20060183756-A1 Pyrrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-08-17 US claimed
WO-2006084634-A1 PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-08-17 WO claimed
US-7361659-B2 Pyrrazolo-pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-04-22 US disclosed
US-20060183756-A1 Pyrrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183756-A1 Pyrrazolo-pyrimidine derivatives GRM1, GRM2, GRM3 KDM4E 2684/4885ALDH1A1 617/4885L3MBTL1 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.